The Peptide Wiki
Mapping Knowledge.
Advancing Discovery.
📩 Subscribe
// STATE LEGISLATION TRACKER

Kentucky SB 164 — AN ACT relating to cannabis.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown
State
Kentucky
Bill
SB 164
Filed
2026-02-05
Read the bill
OpenStates →
Last reviewed
2026-06-21

Plain-English Summary

Kentucky SB 164 is titled as a cannabis bill, and the available subjects do not indicate any peptide-specific content. Based only on the title, subjects, and unavailable latest action, it does not appear to affect compounded peptides, off-label peptide prescribing, telehealth peptide care, NP/naturopathic scope, FDA 503A/503B compounding, or peptide-related monitoring.

Key Points

  • No peptide-specific restriction is visible from the available bill metadata
  • Compounded peptide access does not appear directly affected
  • Off-label peptide prescribing is not implicated by the title or subjects
  • Telehealth peptide care is not mentioned in the available information

What to Watch For

i
Note Watch for the actual bill text before assuming there is no healthcare practice impact.
i
Note If amendments add controlled-substance or prescribing rules, peptide clinicians may need a closer review.
i
Note Cannabis policy changes usually do not affect FDA 503A or 503B peptide compounding directly.

Where the Bill Stands

The provided source reports that the latest OpenStates action refetch failed, so the bill's current procedural status is unknown from the available metadata.
— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.
Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws